TD Asset Management
BIO icon

TD Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

TD Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,780
Closed -$2.73M – 1228
2026
Q1 		$2.73M Buy
9,780
+396
+4% +$114K ﹤0.01% 900
2025
Q4 		$2.84M Buy
9,384
+396
+4% +$124K ﹤0.01% 905
2025
Q3 		$2.52M Buy
8,988
+7,386
+461% +$2.01M ﹤0.01% 917
2025
Q2 		$387K Sell
1,602
-209
-12% -$49.4K ﹤0.01% 1147
2025
Q1 		$441K Buy
1,811
+182
+11% +$54.8K ﹤0.01% 1155
2024
Q4 		$535K Buy
1,629
+280
+21% +$95K ﹤0.01% 1180
2024
Q3 		$448K Sell
1,349
-4,001
-75% -$1.27M ﹤0.01% 1311
2024
Q2 		$1.46M Sell
5,350
-26
-0.5% -$7.56K ﹤0.01% 1083
2024
Q1 		$1.86M Sell
5,376
-129
-2% -$42.4K ﹤0.01% 1050
2023
Q4 		$1.78M Buy
5,505
+431
+8% +$135K ﹤0.01% 1046
2023
Q3 		$1.82M Sell
5,074
-340
-6% -$131K ﹤0.01% 983
2023
Q2 		$2.05M Buy
5,414
+257
+5% +$105K ﹤0.01% 960
2023
Q1 		$2.47M Sell
5,157
-73
-1% -$34.2K ﹤0.01% 919
2022
Q4 		$2.2M Buy
5,230
+64
+1% +$25.8K ﹤0.01% 953
2022
Q3 		$2.16M Sell
5,166
-60
-1% -$29.9K ﹤0.01% 978
2022
Q2 		$2.59M Sell
5,226
-1,945
-27% -$1.01M ﹤0.01% 931
2022
Q1 		$4.04M Buy
7,171
+171
+2% +$103K ﹤0.01% 875
2021
Q4 		$5.29M Sell
7,000
-358
-5% -$268K ﹤0.01% 859
2021
Q3 		$5.49M Sell
7,358
-177
-2% -$133K 0.01% 797
2021
Q2 		$5.57M Buy
7,535
+146
+2% +$88.9K 0.01% 803
2021
Q1 		$4.22M Sell
7,389
-2
-0% -$1.18K ﹤0.01% 878
2020
Q4 		$4.31M Buy
7,391
+224
+3% +$128K 0.01% 831
2020
Q3 		$3.69M Buy
7,167
+2,220
+45% +$1.12M 0.01% 784
2020
Q2 		$2.23M Buy
+4,947
New +$2.18M ﹤0.01% 851
2016
Q4 		– Sell
-12,800
Closed -$2.1M – 1370
2016
Q3 		$2.1M Buy
12,800
+2,100
+20% +$319K ﹤0.01% 868
2016
Q2 		$1.53M Buy
+10,700
New +$1.53M ﹤0.01% 899

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

TD Asset Management's BIO Position: Q2 2026 in Review

TD Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 9,780 shares — an estimated $2.73M sold.

TD Asset Management first reported a position in BIO in Q2 2016 and held it in 26 quarters. The position peaked at $5.57M in Q2 2021. 304 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • TD Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • TD Asset Management sold 9,780 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $2.73M.
  • TD Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2016 and held it in 26 quarters.
  • TD Asset Management's Bio-Rad Laboratories Class A position peaked at $5.57M in Q2 2021.
  • 304 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.